Geron Corporation [NASDAQ: GERN] price plunged by -5.74 percent to reach at -$0.14. The company report on August 22, 2023 at 8:00 AM that Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS.
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 for Geron’s New Drug Application (NDA) for imetelstat for the treatment of transfusion-dependent anemia in patients with lower risk myelodysplastic syndromes (MDS). In addition, the FDA informed the Company that it is currently planning to hold an advisory committee meeting as part of the NDA review.
“We look forward to working with the FDA to complete the NDA review process on a timely basis,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “With the PDUFA date now set, we continue to expect an imetelstat launch in the United States by the end of the first half of 2024, subject to FDA approval.”.
A sum of 8990900 shares traded at recent session while its average daily volume was at 5.52M shares. Geron Corporation shares reached a high of $2.40 and dropped to a low of $2.22 until finishing in the latest session at $2.30.
The one-year GERN stock forecast points to a potential upside of 52.38. The average equity rating for GERN stock is currently 1.70, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Geron Corporation [GERN]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GERN shares is $4.83 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GERN stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Geron Corporation shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on March 28, 2023.
The Average True Range (ATR) for Geron Corporation is set at 0.17, with the Price to Sales ratio for GERN stock in the period of the last 12 months amounting to 2251.56. The Price to Book ratio for the last quarter was 4.18, with the Price to Cash per share for the same quarter was set at 0.76.
GERN Stock Performance Analysis:
Geron Corporation [GERN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.88. With this latest performance, GERN shares dropped by -29.01% in over the last four-week period, additionally sinking by -17.27% over the last 6 months – not to mention a drop of -3.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GERN stock in for the last two-week period is set at 31.04, with the RSI for the last a single of trading hit 29.45, and the three-weeks RSI is set at 33.60 for Geron Corporation [GERN]. The present Moving Average for the last 50 days of trading for this stock 2.98, while it was recorded at 2.36 for the last single week of trading, and 2.76 for the last 200 days.
Insight into Geron Corporation Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Geron Corporation [GERN] shares currently have an operating margin of -23246.64 and a Gross Margin at -45.64. Geron Corporation’s Net Margin is presently recorded at -23808.89.
Return on Total Capital for GERN is now -87.37, given the latest momentum, and Return on Invested Capital for the company is -96.40. Return on Equity for this stock declined to -137.49, with Return on Assets sitting at -68.12. When it comes to the capital structure of this company, Geron Corporation [GERN] has a Total Debt to Total Equity ratio set at 69.69. Additionally, GERN Total Debt to Total Capital is recorded at 41.07, with Total Debt to Total Assets ending up at 29.26. Long-Term Debt to Equity for the company is recorded at 42.35, with the Long-Term Debt to Total Capital now at 24.96.
Reflecting on the efficiency of the workforce at the company, Geron Corporation [GERN] managed to generate an average of -$1,326,178 per employee. Receivables Turnover for the company is 0.24 with a Total Asset Turnover recorded at a value of 0.00.Geron Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.20.
GERN Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GERN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Geron Corporation go to 5.00%.
Geron Corporation [GERN] Institutonal Ownership Details
The top three institutional holders of GERN stocks are: VANGUARD GROUP INC with ownership of 1.31 billion shares, which is approximately 8.2089%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $170.67 trillion in GERN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $150.98 trillion in GERN stock with ownership which is approximately 5.7381%.